Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Mirtazapine":

Mirtazapine in pregnancy and lactation - A systematic review. Smit M et al. Eur Neuropsychopharmacol. (2016)

Mirtazapine for symptom control in refractory gastroparesis. Malamood M et al. Drug Des Devel Ther. (2017)

Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Karsten J et al. J Psychopharmacol. (2017)

Search results

Items: 1 to 20 of 2090

1.

Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease.

Kettunen R, Taipale H, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Koponen M.

Eur J Clin Pharmacol. 2018 Nov 9. doi: 10.1007/s00228-018-2591-5. [Epub ahead of print]

PMID:
30413841
2.

Toxicological findings in suicides - frequency of antidepressant and antipsychotic substances.

Methling M, Krumbiegel F, Hartwig S, Parr MK, Tsokos M.

Forensic Sci Med Pathol. 2018 Nov 5. doi: 10.1007/s12024-018-0041-4. [Epub ahead of print]

PMID:
30397872
3.

Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing.

Macaluso M, Preskorn SH.

J Psychiatr Pract. 2018 Nov;24(6):416-419. doi: 10.1097/PRA.0000000000000345.

PMID:
30395549
4.

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).

Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, Round J, Burns A, Chew-Graham CA, Anderson IM, Shepherd T, Campbell J, Dickens CM, Carter M, Jenkinson C, Macleod U, Gibson H, Davies S, Wiles NJ.

BMJ. 2018 Oct 31;363:k4218. doi: 10.1136/bmj.k4218.

5.

The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.

De La Garza N, Rush AJ, Killian MO, Grannemann BD, Carmody TJ, Trivedi MH.

Depress Anxiety. 2018 Oct 29. doi: 10.1002/da.22855. [Epub ahead of print]

PMID:
30370613
6.

Involvement of 5-HT2A receptor hyperfunction in the anxiety-like behavior induced by doxorubicin and cyclophosphamide combination treatment in rats.

Nakamura Y, Kitamura Y, Sumiyoshi Y, Naito N, Kan S, Ushio S, Miyazaki I, Asanuma M, Sendo T.

J Pharmacol Sci. 2018 Oct 9. pii: S1347-8613(18)30185-3. doi: 10.1016/j.jphs.2018.10.001. [Epub ahead of print]

7.

Sleep-related eating disorder with mirtazapine.

Shinith D, Mathilakath A, Kim DI, Patel B.

BMJ Case Rep. 2018 Oct 21;2018. pii: bcr-2018-224676. doi: 10.1136/bcr-2018-224676.

PMID:
30344142
8.

Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression.

Frolkis AD, Vallerand IA, Shaheen AA, Lowerison MW, Swain MG, Barnabe C, Patten SB, Kaplan GG.

Gut. 2018 Oct 18. pii: gutjnl-2018-317182. doi: 10.1136/gutjnl-2018-317182. [Epub ahead of print]

PMID:
30337374
9.

In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease.

Fitzpatrick RL, Quimby JM, Benson KK, Ramirez D, Sieberg LG, Wittenburg LA, Gustafson DL.

J Vet Intern Med. 2018 Oct 11. doi: 10.1111/jvim.15237. [Epub ahead of print]

10.

Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia.

Poyurovsky M, Weizman A.

J Clin Psychopharmacol. 2018 Dec;38(6):609-611. doi: 10.1097/JCP.0000000000000972.

PMID:
30300293
11.

Effects of cognitive judgement bias and acute antidepressant treatment on sensitivity to feedback and cognitive flexibility in the rat version of the probabilistic reversal-learning test.

Drozd R, Rychlik M, Fijalkowska A, Rygula R.

Behav Brain Res. 2018 Oct 4. pii: S0166-4328(18)31081-7. doi: 10.1016/j.bbr.2018.10.003. [Epub ahead of print]

PMID:
30292902
12.

Mirtazapine for Major Depression Developed After Hyperemesis Gravidarum.

Naguy A.

Am J Ther. 2018 Sep 18. doi: 10.1097/MJT.0000000000000860. [Epub ahead of print] No abstract available.

PMID:
30277906
13.

New developments in the treatment of gastroparesis and functional dyspepsia.

Tack J, Camilleri M.

Curr Opin Pharmacol. 2018 Sep 20;43:111-117. doi: 10.1016/j.coph.2018.08.015. [Epub ahead of print] Review.

PMID:
30245474
14.

Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.

Howard ML, Hossaini R, Tolar C, Gaviola ML.

Ann Pharmacother. 2018 Sep 19:1060028018802816. doi: 10.1177/1060028018802816. [Epub ahead of print]

PMID:
30229678
15.

Stimulant and Designer Drug Use: Primary Care Management.

Klega AE, Keehbauch JT.

Am Fam Physician. 2018 Jul 15;98(2):85-92.

PMID:
30215997
16.

A Case of Musical Hallucinations Related to Mirtazapine.

Lee GH, Stewart JT.

Clin Neuropharmacol. 2018 Nov/Dec;41(6):222-223. doi: 10.1097/WNF.0000000000000302.

PMID:
30204598
17.

Other Antidepressants.

Schwasinger-Schmidt TE, Macaluso M.

Handb Exp Pharmacol. 2018 Sep 8. doi: 10.1007/164_2018_167. [Epub ahead of print]

PMID:
30194544
18.

Older Adults With Unintended Weight Loss: The Role of Appetite Stimulants.

Levitt A, O ľNeil J.

Home Healthc Now. 2018 Sep/Oct;36(5):312-318. doi: 10.1097/NHH.0000000000000692.

PMID:
30192276
19.

Demographic and clinical factors associated with different antidepressant treatments: a retrospective cohort study design in a UK psychiatric healthcare setting.

Fernandes AC, Chandran D, Khondoker M, Dewey M, Shetty H, Dutta R, Stewart R.

BMJ Open. 2018 Sep 5;8(9):e022170. doi: 10.1136/bmjopen-2018-022170.

20.

Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder.

Kamijima K, Yasuda M, Yamamura K, Fukuta Y.

Curr Med Res Opin. 2018 Dec;34(12):2105-2112. doi: 10.1080/03007995.2018.1519317. Epub 2018 Sep 12.

PMID:
30173568

Supplemental Content

Loading ...
Support Center